CFDE Data Portal | Search SLC35E2B

	Label	Description
	SLC35E2B Gene (Entity type)	ENSG00000189339 - solute carrier family 35 member E2B
	SLC35E2B associations Collection (Entity type)	Associations for SLC35E2B_associations
	SLC35E2B associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE166914 1 V 2 ABEMACICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE150244 TRIM8 knockout 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

SLC35E2B

ENSG00000189339 - solute carrier family 35 member E2B

SLC35E2B associations

Associations for SLC35E2B_associations

SLC35E2B associations.tsv

A file from IDG as part of the Harmonizome project

GSE166914 1 V 2 ABEMACICLIB HUMAN DN

A Gene Set from LINCS

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE150244 TRIM8 knockout 3 v 0 human dn

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.